中国紫杉类药物剂量密集化疗方案临床应用专家共识

2019-11-30 中国抗癌协会 中国癌症杂志.2019,29(11):910-920.

紫杉类抗肿瘤药物是目前抗肿瘤领域广泛应用的药物之一,在全球多癌种治疗中占据重要地位。近年来,各国学者们通过改变给药模式、药物组合方式或剂量等,探索紫杉类药物最佳临床治疗方案,其中最为显著的成果即为剂量密集化疗。为进一步提高临床医师对紫杉类药物剂量密集化疗方案的认识,更好地指导临床合理用药,肿瘤专家基于循证医学证据,制定本次《中国紫杉类药物剂量密集化疗方案临床应用专家共识》。

中文标题:

中国紫杉类药物剂量密集化疗方案临床应用专家共识

发布机构:

中国抗癌协会

发布日期:

2019-11-30

简要介绍:

紫杉类抗肿瘤药物是目前抗肿瘤领域广泛应用的药物之一,在全球多癌种治疗中占据重要地位。近年来,各国学者们通过改变给药模式、药物组合方式或剂量等,探索紫杉类药物最佳临床治疗方案,其中最为显著的成果即为剂量密集化疗。为进一步提高临床医师对紫杉类药物剂量密集化疗方案的认识,更好地指导临床合理用药,肿瘤专家基于循证医学证据,制定本次《中国紫杉类药物剂量密集化疗方案临床应用专家共识》。

 

拓展指南:化疗相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国紫杉类药物剂量密集化疗方案临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=c660e1c0018a608e, title=中国紫杉类药物剂量密集化疗方案临床应用专家共识, enTitle=, guiderFrom=中国癌症杂志.2019,29(11):910-920., authorId=null, author=, summary=紫杉类抗肿瘤药物是目前抗肿瘤领域广泛应用的药物之一,在全球多癌种治疗中占据重要地位。近年来,各国学者们通过改变给药模式、药物组合方式或剂量等,探索紫杉类药物最佳临床治疗方案,其中最为显著的成果即为剂量密集化疗。为进一步提高临床医师对紫杉类药物剂量密集化疗方案的认识,更好地指导临床合理用药,肿瘤专家基于循证医学证据,制定本次《中国紫杉类药物剂量密集化疗方案临床应用专家共识》。 , cover=, journalId=null, articlesId=null, associationId=18, associationName=中国抗癌协会, associationIntro=中国抗癌协会是中国科学技术协会主管、中华人民共和国民政部注册登记、具有独立法人资格的肿瘤学科唯一的国家一级学会。成立以来积极开展肿瘤学科的临床与基础性研究,创建肿瘤专业继续教育基地,创办多种形式的肿瘤学习培训班,积极推广新成果、新技术,举办国内外肿瘤学术会议,为国内外肿瘤研究者提供了广阔的学术交流平台,促进了我国肿瘤防治水平的提高。, copyright=0, guiderPublishedTime=Sat Nov 30 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>紫杉类抗肿瘤药物是目前抗肿瘤领域广泛应用的药物之一,在全球多癌种治疗中占据重要地位。近年来,各国学者们通过改变给药模式、药物组合方式或剂量等,探索紫杉类药物最佳临床治疗方案,其中最为显著的成果即为剂量密集化疗。为进一步提高临床医师对紫杉类药物剂量密集化疗方案的认识,更好地指导临床合理用药,肿瘤专家基于循证医学证据,制定本次《中国紫杉类药物剂量密集化疗方案临床应用专家共识》。 </P> <P> </P>拓展指南:<strong>与<font color=red>化疗</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=1ef331c0018353a5" title="转移性前列腺癌化疗中国专家共识(2019版)" target=_blank>转移性前列腺癌化疗中国专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=617ef1c0018302cf" title="中国肿瘤化疗相关贫血诊治专家共识(2019年版)" target=_blank>中国肿瘤化疗相关贫血诊治专家共识(2019年版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=ac10c1c001e72a05" title="肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤专家共识" target=_blank>肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=9c26d1c001ea57d4" title="耐药结核病化疗过程中药品不良反应处理的专家共识" target=_blank>耐药结核病化疗过程中药品不良反应处理的专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=bfd121c001e11117" title="妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)" target=_blank>妇科恶性肿瘤腹腔热灌注化疗临床应用专家共识(2019)</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E5%8C%96%E7%96%97" target=_blank>有关化疗更多指南</a></ul>, tagList=[TagDto(tagId=94932, tagName=紫杉类药物), TagDto(tagId=98287, tagName=剂量密集化疗方案), TagDto(tagId=611, tagName=临床应用)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3816, appHits=183, showAppHits=10, pcHits=2301, showPcHits=2248, likes=58, shares=5, comments=4, approvalStatus=1, publishedTime=Mon Dec 30 23:20:29 CST 2019, publishedTimeString=2019-11-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Dec 30 23:20:29 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 01:30:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国紫杉类药物剂量密集化疗方案临床应用专家共识)])
中国紫杉类药物剂量密集化疗方案临床应用专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=944242, encodeId=e281944242f7, content=学习了,学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Sun Feb 28 17:26:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919605, encodeId=5656919605d8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:03:49 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378177, encodeId=abd53e81772b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jan 15 16:47:10 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377625, encodeId=b1553e76254c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 31 07:53:20 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2021-02-28 医海无涯苦作舟

    学习了,学习了。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=944242, encodeId=e281944242f7, content=学习了,学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Sun Feb 28 17:26:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919605, encodeId=5656919605d8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:03:49 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378177, encodeId=abd53e81772b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jan 15 16:47:10 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377625, encodeId=b1553e76254c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 31 07:53:20 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2021-01-25 ms4000001831181033

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=944242, encodeId=e281944242f7, content=学习了,学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Sun Feb 28 17:26:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919605, encodeId=5656919605d8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:03:49 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378177, encodeId=abd53e81772b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jan 15 16:47:10 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377625, encodeId=b1553e76254c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 31 07:53:20 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2020-01-15 145fad5em27暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=944242, encodeId=e281944242f7, content=学习了,学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201031/7569b126444c4b1b9ab8cbd298657008/59c094a3153443d698ed34d3414795a2.jpg, createdBy=eb1f5428506, createdName=医海无涯苦作舟, createdTime=Sun Feb 28 17:26:41 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919605, encodeId=5656919605d8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db705444952, createdName=ms4000001831181033, createdTime=Mon Jan 25 07:03:49 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378177, encodeId=abd53e81772b, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c955103013, createdName=145fad5em27暂无昵称, createdTime=Wed Jan 15 16:47:10 CST 2020, time=2020-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377625, encodeId=b1553e76254c, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 31 07:53:20 CST 2019, time=2019-12-31, status=1, ipAttribution=)]
    2019-12-31 thm112988

    0